Bio-Techne (TECH) Non-Current Deferred Tax Liability (2011 - 2026)
Bio-Techne (TECH) posted quarterly Non-Current Deferred Tax Liability of $14.2 million for Q1 2026, down 55.49% year-over-year from $31.9 million in Q1 2025, and up 28.94% quarter-over-quarter from $11.0 million in Q4 2025.
Bio-Techne (TECH) Non-Current Deferred Tax Liability (2011 - 2026) Analysis & Trends
Bio-Techne's Non-Current Deferred Tax Liability history runs 16 years deep, the most recent figure standing at $14.2 million for Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability fell 55.49% year-over-year to $14.2 million; the TTM figure through Mar 2026 stood at $14.2 million (down 55.49% YoY), while the FY2025 annual figure was $6.2 million, down 88.96% from the prior year.
- Non-Current Deferred Tax Liability for Q1 2026 stood at $14.2 million, up from $11.0 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $112.9 million in Q3 2022, with the low at $4.1 million in Q3 2023.
- The 5-year median for Non-Current Deferred Tax Liability is $55.9 million (2024), against an average of $56.7 million.
- The sharpest annual moves came in 2023 and 2024: Non-Current Deferred Tax Liability tumbled 96.37% in 2023, then jumped 1119.93% in 2024.
- Bio-Techne's Non-Current Deferred Tax Liability stood at $111.4 million in 2022, then tumbled by 35.74% to $71.6 million in 2023, then sank by 47.3% to $37.7 million in 2024, then sank by 70.78% to $11.0 million in 2025, then increased by 28.94% to $14.2 million in 2026.
- Business Quant data shows TECH's Non-Current Deferred Tax Liability at $14.2 million in Q1 2026, $11.0 million in Q4 2025, and $11.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Bio-Techne | 11.33 Bn | 11.12 Bn | 208.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.21 Mn |
| Mar 31, 2026 | 14.21 Mn |
| Dec 31, 2025 | 11.02 Mn |
| Dec 31, 2025 | 11.02 Mn |
| Sep 30, 2025 | 11.27 Mn |
| Sep 30, 2025 | 11.27 Mn |
| Jun 30, 2025 | 6.17 Mn |
| Jun 30, 2025 | 6.17 Mn |
| Mar 31, 2025 | 31.92 Mn |
| Mar 31, 2025 | 31.92 Mn |
| Dec 31, 2024 | 37.72 Mn |
| Dec 31, 2024 | 37.72 Mn |
| Sep 30, 2024 | 50.02 Mn |
| Sep 30, 2024 | 50.02 Mn |
| Jun 30, 2024 | 55.86 Mn |
| Jun 30, 2024 | 55.86 Mn |
| Mar 31, 2024 | 63.67 Mn |
| Mar 31, 2024 | 63.67 Mn |
| Dec 31, 2023 | 71.58 Mn |
| Dec 31, 2023 | 71.58 Mn |